FDA-cleared biomarker test for pediatric acute kidney injury risk assessment. Available for use on Roche Diagnostics Cobas c 501 clinical chemistry analyzer to rapidly identify kidney damage in pediatric patients.
Manufactured by
BioPorto Diagnostics
United States
ProNephro AKI (NGAL) is designed to aid in the risk assessment of acute kidney injury (AKI) in ICU patients 3 months to 22 years. A low NGAL value indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI and can trigger nephrology consults and interventions 2-3 days before serum creatinine rises.
© 2026 Suplivia · Home · Browse Products